Methotrexate reduces levels of pentosidine & 8-hydroxy-deoxy guanosine in patients with RA

[Guest guest]

Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine

in patients with rheumatoid arthritis

www.springerlink.com/content/m30n55x411q1q3vl/?p=4e722f5d368341c7a75e6b3e5634247\

7 & pi=9

JournalModern Rheumatology

PublisherSpringer Japan

ISSN1439-7595 (Print) 1439-7609 (Online)

IssueVolume 17, Number 5

Abstract

This study was performed to investigate whether methotrexate (MTX) affects

the levels of oxidative stress markers, including pentosidine one of the

glycation end products (AGEs) or 8-hydroxy-deoxy guanosine (8-OHdG).

These stress markers represent DNA damage; 19 rheumatoid arthritis (RA)

patients underwent MTX treatment.

The levels of serum total, urinary total, urinary-free pentosidine and also

urinary 8-OHdG, as well as clinical parameters, including disease activity

scores for 28 joints (DAS28) were measured at baseline and at 3 and 6 months

after the initial treatment with MTX.

After the initial treatment with MTX, serum total and urinary total

pentosidine levels were reduced at 6 months, and urinary-free pentosidine

levels were reduced at 3 and 6 months. Urinary 8-OHdG levels also were

significantly reduced at 6 months after the initial treatment with MTX.

This study demonstrated that MTX plays a role as a regulator against

pentosidine formation and oxidative DNA damage in RA patients.